Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug ...

Telitacicept, a dual inhibitor of the cytokines B-lymphocyte stimulator and a proliferation-inducing ligand, showed efficacy ...

Johnson & Johnson JNJ announced that the phase IIb JASMINE study, which evaluated its pipeline candidate, nipocalimab, for ...

Which of the statements about the 2025 American College of Rheumatology guideline for the treatment of systemic lupus ...

Positive full results from the Phase III TULIP-SC trial showed the subcutaneous administration of Saphnelo demonstrated a statistically ...

Over 3.4 million people globally are affected by SLE, and it is one of the leading causes of death in young women in the US ...

Systemic lupus erythematosus (SLE) is the most common form of lupus — it’s the type that 7 in 10 people with lupus have. It's what most people mean when they say "lupus." Experts don’t know what ...

Systemic lupus erythematosus (SLE) is a potentially fatal, chronic, multisystem autoimmune disorder that typically affects women between puberty and menopause. Defects can occur in many parts of the ...

AN understanding of the interrelations of pregnancy and systemic lupus erythematosus is of considerable clinical importance, particularly since the disease occurs most frequently in women during the ...